JP2005523335A - 高齢被検体の不安障害および気分障害の治療方法 - Google Patents
高齢被検体の不安障害および気分障害の治療方法 Download PDFInfo
- Publication number
- JP2005523335A JP2005523335A JP2003587405A JP2003587405A JP2005523335A JP 2005523335 A JP2005523335 A JP 2005523335A JP 2003587405 A JP2003587405 A JP 2003587405A JP 2003587405 A JP2003587405 A JP 2003587405A JP 2005523335 A JP2005523335 A JP 2005523335A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- antibody
- seq
- xaa
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37546202P | 2002-04-25 | 2002-04-25 | |
| PCT/US2003/010473 WO2003090772A1 (en) | 2002-04-25 | 2003-04-17 | Method for treating anxiety and mood disorders in older subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523335A true JP2005523335A (ja) | 2005-08-04 |
| JP2005523335A5 JP2005523335A5 (cg-RX-API-DMAC7.html) | 2006-06-01 |
Family
ID=29270644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587405A Ceased JP2005523335A (ja) | 2002-04-25 | 2003-04-17 | 高齢被検体の不安障害および気分障害の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129691A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1501531B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005523335A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE419871T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003223474B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2483729A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325717D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2318123T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003090772A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| AU2005290250A1 (en) * | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| US20060153772A1 (en) * | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| NZ568012A (en) * | 2005-12-12 | 2012-07-27 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| RU2498999C2 (ru) * | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| HRP20150086T1 (xx) * | 2007-06-12 | 2015-02-27 | Ac Immune S.A. | Humanizirana antitijela za beta amiloid |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| PL2238166T3 (pl) * | 2007-10-05 | 2014-07-31 | Genentech Inc | Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu |
| AU2008311366B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019196A1 (en) * | 1992-03-24 | 1993-09-30 | British Technology Group Ltd. | ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY |
| WO2001062801A2 (en) * | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5837672A (en) * | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| JP5249482B2 (ja) * | 1999-06-16 | 2013-07-31 | ボストン・バイオメデイカル・リサーチ・インステイテユート | インビボのβ−アミロイドレベルの免疫学的制御 |
| US7166478B2 (en) * | 2002-03-12 | 2007-01-23 | Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses |
-
2003
- 2003-04-17 ES ES03719604T patent/ES2318123T3/es not_active Expired - Lifetime
- 2003-04-17 EP EP03719604A patent/EP1501531B1/en not_active Revoked
- 2003-04-17 JP JP2003587405A patent/JP2005523335A/ja not_active Ceased
- 2003-04-17 WO PCT/US2003/010473 patent/WO2003090772A1/en not_active Ceased
- 2003-04-17 AT AT03719604T patent/ATE419871T1/de not_active IP Right Cessation
- 2003-04-17 DE DE60325717T patent/DE60325717D1/de not_active Revoked
- 2003-04-17 AU AU2003223474A patent/AU2003223474B2/en not_active Ceased
- 2003-04-17 US US10/512,527 patent/US20050129691A1/en not_active Abandoned
- 2003-04-17 CA CA002483729A patent/CA2483729A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019196A1 (en) * | 1992-03-24 | 1993-09-30 | British Technology Group Ltd. | ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY |
| WO2001062801A2 (en) * | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE419871T1 (de) | 2009-01-15 |
| WO2003090772A1 (en) | 2003-11-06 |
| CA2483729A1 (en) | 2003-11-06 |
| EP1501531A1 (en) | 2005-02-02 |
| AU2003223474B2 (en) | 2008-09-04 |
| US20050129691A1 (en) | 2005-06-16 |
| AU2003223474A1 (en) | 2003-11-10 |
| DE60325717D1 (de) | 2009-02-26 |
| EP1501531A4 (en) | 2006-02-15 |
| EP1501531B1 (en) | 2009-01-07 |
| ES2318123T3 (es) | 2009-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003223474B2 (en) | Method for treating anxiety and mood disorders in older subjects | |
| EP1793671B1 (en) | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity | |
| ES2253839T3 (es) | Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer. | |
| AU778360B2 (en) | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue | |
| US20060073149A1 (en) | Rapid improvement of cognition in condition related to abeta | |
| HUE035385T2 (en) | Treatment for peanut allergy | |
| Sopala et al. | Chronic cerebral hypoperfusion in the rat enhances age-related deficits in spatial memory | |
| Junqueira et al. | Inosine, an endogenous purine nucleoside, suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis: a role for A2A adenosine receptor | |
| KR20030096227A (ko) | 신경 및 신경정신 질환의 치료방법 | |
| JP2022514510A (ja) | うつ病の治療方法 | |
| US20190298740A1 (en) | Methods and compositions for treating hallucinations and conditions related to the same | |
| Bradford et al. | A treatment for impulse control disorders and paraphilia: a case report | |
| KR20230086674A (ko) | 파킨슨 질환의 치료 | |
| AU2003218206B2 (en) | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies | |
| Cabral et al. | TNFR1-mediated neuroinflammation is necessary for respiratory deficits observed in 6-hydroxydopamine mouse model of Parkinsońs Disease | |
| JP4637744B2 (ja) | 神経成長因子の投与により心理状態を治療する方法 | |
| US20200129528A1 (en) | Methods for treating blood pressure conditions using aminosterol compositions | |
| US20200038420A1 (en) | Aminosterol compositions and methods of using the same for treating depression | |
| Bhatia et al. | 1. An Uncommon Case of Zoophilia | |
| PHARMACOLOGY-BRANCH-VI | THE COMPARATIVE STUDY OF EFFECT OF SITAGLIPTIN AND VILDAGLIPTIN ON GLYCAEMIC CONTROL AND SERUM LIPID LEVEL IN TYPE II DIABETES MELLITUS PATIENTS IN A RURAL TERTIARY CARE HOSPITAL | |
| Krogulski et al. | Simultaneous use of sertraline and hormonal replacement therapy (HRT) in women with major depression during the menopausal period | |
| Washington | Production, accumulation and clearance of amyloid-beta after experimental traumatic brain injury | |
| Scruggs | Effects of interleukin-1 receptor antagonist in aged rats on spatial learning in the Morris water maze | |
| COMMON | 2 MAKING SENSE OF SEROTONIN (5HT) AND ITS ROLE IN COMMON PSYCHOPATHOLOGY JF William Deakin | |
| Argento | Effect of exposure to methylphenidate in early life on cocaine reward in adulthood: a possible role for netrin-1 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060406 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060406 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090831 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100217 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100316 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20100727 |